We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Next Generation Sequencing Will Be Efficient and Cost-Effective

By LabMedica International staff writers
Posted on 03 Jul 2012
Next-generation sequencing (NGS) is being created for use in clinical research and molecular diagnostics.

Qiagen (Hilden, Germany, and Germantown, MA, USA) is in the advanced stages of creating sample-to-result, efficient, and cost-effective NGS workflow solutions.

A broad range of Qiagen products include automated sample preparation solutions (nucleic acid extraction, DNA enrichment, library preparation, and targeted gene analysis panels)–with a next-generation benchtop sequencer in development with Intelligent Bio-Systems, Inc., (Waltham, MA, USA) a privately held company that Qiagen has acquired.

New bioinformatics, including solutions emerging from collaboration with SAP AG (Walldorf, Germany) will be incorporated into the workflows. More...
A first sample-to-result NGS solution is expected to be launched next year, while details on specifications and launch plans are set to be released in early 2013.

In the first wave, Qiagen plans to offer eight preconfigured gene panels for use in cancer, as well as enable customers to create customized panels for specific molecular pathways and diseases.

A new system will offer a new dimension of benefits and cost savings. Key features include new sample technologies and software as well as the ability to process up to 20 individual samples in parallel without a need for pooling and bar coding, which can result in significant time and cost savings in clinical sequencing.

Qiagen intends to offer this new product portfolio across all of its customer classes, with priority focus on clinical research in academia and pharma as well as in some molecular diagnostics franchises, including select areas of personalized healthcare.

The next-generation sequencing market, which up to this point has been driven primarily by life sciences research, is estimated to be more than USD 1 billion a year and growing rapidly as the use of these technologies expands into new areas.

Related Links:

Qiagen
Intelligent Bio-Systems
SAP AG



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Platelet Function Analyzer
PL-12
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.